Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,159 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,025 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (560)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04723004 | Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC | completed | Phase 3 | 326 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 2 | Jul 13, 2026 | clinicaltrials |
| NCT05301842 | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC(EMERALD-3) | active not recruiting | Phase 3 | 760 | AstraZenecaINDUSTRY | 22 | Jul 13, 2026 |
| clinicaltrials |
| NCT06109779 | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | active not recruiting | Phase 3 | 760 | AstraZenecaINDUSTRY | 21 | Jul 10, 2026 | clinicaltrials |
| NCT04523493 | Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC | active not recruiting | Phase 3 | 530 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 5 | Jul 6, 2026 | clinicaltrials |
| NCT05948475 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma(FIRST-308) | active not recruiting | Phase 3 | 200 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 13 | Jul 6, 2026 | clinicaltrials |
| NCT03186898 | Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer | active not recruiting | Phase 3 | 115 | NRG OncologyOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT00980460 | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | completed | Phase 3 | 236 | National Cancer Institute (NCI)NIH | 6 | Jun 30, 2026 | clinicaltrials |
| NCT05557838 | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC(TREMENDOUS) | active not recruiting | Phase 3 | 214 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01015833 | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 3 | 356 | National Cancer Institute (NCI)NIH | 3 | Jun 24, 2026 | clinicaltrials |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation(IMbrave050) | completed | Phase 3 | 668 | Hoffmann-La RocheINDUSTRY | 26 | Jun 18, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT06900543 | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere(CHEERS) | active not recruiting | Phase 3 | 108 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02562755 | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone(PHOCUS) | completed | Phase 3 | 459 | SillaJen, Inc.INDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07594340 | HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) | recruiting | Phase 3 | 300 | Binkui LiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07598318 | Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations | not yet recruiting | Phase 2 / Phase 3 | 164 | Sir Run Run Shaw HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT03017326 | Paediatric Hepatic International Tumour Trial(PHITT) | active not recruiting | Phase 3 | 450 | University of BirminghamOTHER | 14 | May 13, 2026 | clinicaltrials |
| NCT04478292 | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy | recruiting | Phase 3 | 330 | Shanghai Children's Medical CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07322848 | DEB-TACE vs cTACE in HCC After TIPS(UPGRADE) | recruiting | Phase 3 | 206 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07537946 | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer | not yet recruiting | Phase 3 | 400 | Tongji HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07490262 | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. | recruiting | Phase 2 / Phase 3 | 680 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04924062 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study | completed | Phase 3 | 158 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06485466 | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 101 | Guohui XuOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02771405 | Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC(FRI-STC) | completed | Phase 3 | 150 | National Hepatology & Tropical Medicine Research InstituteOTHER_GOV | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07293468 | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)(BIIRTH) | recruiting | Phase 2 / Phase 3 | 106 | Tuen Mun HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT00116454 | Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis(Lipiocis) | completed | Phase 3 | 73 | ANRS, Emerging Infectious DiseasesOTHER_GOV | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02435953 | TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma(TORCH) | completed | Phase 3 | 241 | Ming ZhaoOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04003636 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)(KEYNOTE-966) | completed | Phase 3 | 1,069 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Mar 24, 2026 | clinicaltrials |
| NCT04720716 | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | completed | Phase 3 | 344 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07461675 | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection | not yet recruiting | Phase 3 | 30 | University of Geneva, SwitzerlandOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | terminated | Phase 3 | 45 | Translational Research in OncologyOTHER | 13 | Mar 9, 2026 | clinicaltrials |
| NCT05665348 | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy(TRIPLET) | completed | Phase 2 / Phase 3 | 229 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07437287 | Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers(CROCOBIL) | not yet recruiting | Phase 2 / Phase 3 | 160 | UNICANCEROTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07417397 | Adjuvant TACE in HCC With High-risk Recurrence Factors | recruiting | Phase 3 | 442 | Guangxi Medical UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07392866 | A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 120 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03713593 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | completed | Phase 3 | 794 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 5, 2026 | clinicaltrials |
| NCT06904170 | Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma(ALICE) | recruiting | Phase 2 / Phase 3 | 196 | UNICANCEROTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT01730937 | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | completed | Phase 3 | 193 | Radiation Therapy Oncology GroupNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT07229625 | A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) | recruiting | Phase 3 | 604 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05198609 | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | active not recruiting | Phase 3 | 214 | Sun Yat-sen UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06591520 | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer | active not recruiting | Phase 3 | 682 | AkesoINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07356037 | Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 68 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05153785 | Perioperative Intravenous Lidocaine in Liver Surgery | completed | Phase 2 / Phase 3 | 124 | Lund University HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | completed | Phase 3 | 452 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07328919 | Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | not yet recruiting | Phase 3 | 138 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)(SKYSCRAPER-14) | active not recruiting | Phase 3 | 687 | Hoffmann-La RocheINDUSTRY | 27 | Dec 31, 2025 | clinicaltrials |
| NCT04639180 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | active not recruiting | Phase 3 | 687 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07309419 | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma(Cocktail-001) | not yet recruiting | Phase 2 / Phase 3 | 222 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 30, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials